This trial is designed to assess the tolerability, safety, pharmacokinetic profile, and preliminary efficacy of the combination of ZGGS18 and ZG005 in patients with advanced solid tumors, including advanced cervical cancer, hepatocellular carcinoma, neuroendocrine cancer, and lung cancer.
Fully understand this study and voluntarily sign the ICF.
Age 18-75 years, no gender restriction.
Patients with advanced solid tumors who have failed standard treatment or are intolerant to standard treatment, as confirmed by histopathology or cytology.
Medical history, CT scan, or MRI indicates the presence of CNS metastases.
Other malignancies within 5 years.
Any other reason deeming the participant unsuitable for the study, as judged by the investigator.
Sequential
ZGGS18 for Injection
Biological/VaccineIntravenous infusion
ZG005 for Injection
Biological/VaccineIntravenous infusion
Dose limited toxicity(DLT)
Incidence and severity of DLT events
Adverse Event (AE)
Abnormal changes in clinical symptoms, vital signs, physical examination, laboratory tests, electrocardiograph and other examinations.
Maximum tolerated dose(MTD)
Recommended phase II dose(RP2D)
Objective response rate (ORR)
Objective Response Rate as Assessed by Investigator according to RECIST v1.1
Immunogenicity
Incidence of antidrug antibodies (ADA)
Click on the lead sponsor to view all of their trials.
